A Phase 1/2A Open-Label Study of Pralatrexate and Gemcitabine in Patients with Relapsed or Refractory Lympboprolifierative Malignancies

被引：0

作者：

Horwitz, Steven M. ^{[1
]}

Vose, Julie M. ^{[2
]}

Advani, Ranjana ^{[3
]}

Sankhala, Kamalesh ^{[4
]}

Padmanabhan, Swaminathan ^{[5
]}

Hamlin, Paul A., Jr. ^{[1
]}

Chen, Andy ^{[6
]}

Wilroy, Shannon

Zain, Jasmine M.

Wright, Danielle

Weissbrot, Hanna ^{[1
]}

Hohenstein, Maribeth ^{[2
]}

Cagnoni, Pablo J.

Saunders, Michael E. ^{[7
]}

O'Connor, Owen A. ^{[8
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA

[2] Univ Nebraska Med Ctr, Omaha, NE USA

[3] Stanford Univ, Stanford, CA 94305 USA

[4] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA

[5] Canc Therapy & Res Ctr S Texas, Inst Drug Dev, San Antonio, TX 78229 USA

[6] Stanford Canc Ctr, Palo Alto, CA USA

[7] Allos Therapeut Inc, Westminster, CO USA

[8] CUMC, New York, NY USA

来源：

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：557 / 557

页数：1